William Fodor

GlyGenix Therapeutics, Inc. focuses on treating and curing Glycogen storage diseases. The firm’s services include development of nucleic acid molecules that compensate or correct the genetic defects that cause Glycogen storage disease type 1a. The company was founded by David Feldman and Peter Kaufman in 2006 and is headquartered in Woodbridge, CT.

Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA.

ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA.